"We will want to make sure our regulations continue to work together. This will be essential for everything from getting new drugs to patients quickly to maintaining financial stability."
U.K. Prime Minister Theresa May, who has committed to the U.K. remaining part of the EMA's system of drug regulation and to making a financial contribution to the agency after Brexit

"We want to build the Genentech of small molecules, and we want to do it San Diego. There are 19,000 proteins in the human proteome and I would say that 99.999 percent of the proteins remains free for us to pursue. It's very important to us to have wholly owned programs that go to the market. We could create an inexhaustible pipeline and we wanted to make sure that the deal did not constrain that potential."
Diego Miralles, CEO, Vividion Therapeutics Inc., commenting on the deal that brought $101 million up front from Celgene Corp., which included an equity investment as part of the amount

"This administration and this president are not interested in incremental steps. We are unafraid of disrupting existing arrangements simply because they're backed by powerful special interests. Simply put, our current system may be working for many. But it's not working for patients and it's not working for the taxpayer."
Health and Human Services (HHS) Secretary Alex Azar

"Novartis aims to run studies in ways that overcome many of the barriers patients face when deciding whether or not to enroll in clinical trials, like long journeys or extensive time spent at hospitals or trial sites."
Rob Kowalski, Novartis' ad interim head of global drug development and chief medical officer, on the collaboration with Science 37 Inc., a virtual trials specialist, to initiate up to 10 new clinical trials over the next three years